CombiMatrix Launches Targeted Array for Prenatal Analysis
16 Diciembre 2014 - 7:00AM
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics
company specializing in DNA-based testing services for pre- and
postnatal developmental disorders, today announced the launch of
its Targeted Array for Prenatal Analysis. This new test offers the
superior diagnostic power of microarray analysis for the detection
of clinically relevant microdeletion and microduplication
disorders, while minimizing the risk of identifying a variant of
uncertain significance (VOUS) on chorionic villus sampling (CVS)
and amniocentesis samples.
"Feedback from genetic counselors and maternal fetal medicine
specialists that utilize our prenatal diagnostic tests has been
incredibly positive," said Mark McDonough, President and Chief
Executive Officer of CombiMatrix. "However, these tests provide a
significant amount of information. Genetic counselors have
requested a test option that focuses on the chromosomal
abnormalities that are clinically meaningful to their practices so
that they can more efficiently communicate the results and
recommended next steps to their patients, and this array offers
this advantage. This launch enables CombiMatrix to continue to
build momentum and position ourselves as a leader in the prenatal
diagnostic testing market. As a high-touch laboratory focused on
the needs of our customers, we have responded to the requests of
clinicians to offer this targeted approach in our continuous effort
to be their best partner in patient care."
CombiMatrix will begin accepting samples for this test effective
immediately.
About CombiMatrix Corporation
CombiMatrix Corporation provides valuable molecular diagnostic
solutions and comprehensive clinical support for the highest
quality of care – specializing in miscarriage analysis, prenatal
and pediatric healthcare. CombiMatrix offers comprehensive testing
services for the detection of abnormalities of genes at the DNA
level beyond what can be identified through traditional
technologies. The Company performs genetic testing utilizing
microarray, FISH, PCR and G-Band chromosome analyses. Additional
information about CombiMatrix is available at www.combimatrix.com
or by calling 1-800-710-0624.
Safe Harbor Statement under the Private Securities
Litigation Reform Act of 1995
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. These statements are
based upon our current expectations, speak only as of the date
hereof and are subject to change. All statements, other than
statements of historical fact included in this press release, are
forward-looking statements. Forward-looking statements can often be
identified by words such as "anticipates," "expects," "intends,"
"plans," "goal," "predicts," "believes," "seeks," "estimates,"
"may," "will," "should," "would," "could," "potential," "continue,"
"ongoing," "objective," similar expressions, and variations or
negatives of these words. These forward-looking statements are not
guarantees of future results and are subject to risks,
uncertainties and assumptions that could cause our actual results
to differ materially and adversely from those expressed in any
forward-looking statement. The risks and uncertainties referred to
above include, but are not limited to: market acceptance of our
targeted array for prenatal analysis by genetic counselors and
maternal fetal medicine specialists; our ability to successfully
expand the base of our customers and strategic partners, add to the
menu of our diagnostic tests in both of our primary markets,
develop and introduce new tests and related reports, optimize the
reimbursements received for our testing services, and increase
operating margins by improving overall productivity and expanding
sales volumes; our ability to successfully accelerate sales,
steadily increase the size of our customer rosters; our ability to
attract and retain a qualified sales force; rapid technological
change in our markets; changes in demand for our future services;
legislative, regulatory and competitive developments; general
economic conditions; and various other factors. Further information
on potential factors that could affect our financial results is
included in our Annual Report on Form 10-K, Quarterly Reports of
Form 10-Q, and in other filings with the Securities and Exchange
Commission. We undertake no obligation to revise or update publicly
any forward-looking statements for any reason, except as required
by law.
CONTACT: Company Contact:
Mark McDonough
President & CEO, CombiMatrix Corporation
(949) 753-0624
Investor Contact:
Robert Flamm, Ph.D.
Russo Partners, LLC
(212) 845-4226
robert.flamm@russopartnersllc.com
Media Contact:
David Schull or Lena Evans
Russo Partners LLC
(212) 845-4271
david.schull@russopartnersllc.com
lena.evans@russopartnersllc.com
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Gráfica de Acción Histórica
De Jul 2024 a Jul 2024
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024